Astellas Backed By Full Pipeline To Battle Japan Price Controls and Slow Approvals In U.S.
This article was originally published in PharmAsia News
Executive Summary
Astellas' user fee date for immunosuppressant Prograf MR (tacrolimus) NDA pending at the U.S. FDA has been extended for another three months, the company told a third quarter earnings call Feb.1 at its headquarters in Tokyo